91(top 1%)
papers
1.8K(top 1%)
citations
20(top 1%)
h-index
41(top 1%)
g-index
107
all documents
2.0K
doc citations
601
citing journals

Top Articles

#TitleJournalYearCitations
1Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 FamiliesJournal of Clinical Oncology2020270
2Genomic landscape and chronological reconstruction of driver events in multiple myelomaNature Communications2019183
3Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseBlood2018172
4Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsLeukemia2018137
5Timing the initiation of multiple myelomaNature Communications202099
6Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).Journal of Clinical Oncology202086
7Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialJournal of Clinical Oncology202376
8Wilms tumourNature Reviews Disease Primers202175
9Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trialAnnals of Oncology201965
10Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group–International Society of Paediatric Oncology Wilms' tumour protocol databaseLancet Oncology, The201859
11Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNAJournal of Molecular Diagnostics201845
12Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesClinical Cancer Research202135
13Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.Journal of Clinical Oncology202033
14Cell cycle and apoptosis regulator 2 at the interface between DNA damage response and cell physiologyMutation Research - Reviews in Mutation Research201832
15Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancerJournal of Cellular Physiology201931
16Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative ReviewCancers202029
17Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trialsCancer Medicine202029
18Prognostic Factors for Wilms Tumor Recurrence: A Review of the LiteratureCancers202127
19Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy FailureCells202026
20Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experienceCancer and Metastasis Reviews201922
21Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast CancerCancers201922
22One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-AnalysisOncologist201921
23Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing DataOncologist202120
24SARS‐CoV‐2 disease and children under treatment for cancerPediatric Blood and Cancer202019
25Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adultsExpert Review of Clinical Pharmacology201918
26Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meetingEuropean Journal of Cancer202118
27<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)Haematologica202118
28Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cellsMAbs201817
29Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusEuropean Journal of Cancer202217
30Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaEuropean Journal of Cancer202216
31Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple MyelomaHemaSphere202015
32ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracyESMO Open202015
33O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)Annals of Oncology202014
34Fifty years of clinical and research studies for childhood renal tumors within the International Society of Pediatric Oncology (SIOP)Annals of Oncology202114
35Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian CancerCancers202013
36Sport activities and exercise as part of routine cancer care in children and adolescentsPediatric Blood and Cancer201912
37DICER1-associated malignancies mimicking germ cell neoplasms: Report of two cases and review of the literaturePathology Research and Practice202112
38Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein InteractionFrontiers in Oncology201811
39Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartmentCellular Oncology (Dordrecht)201911
40Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients202111
41Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsGenetics in Medicine202210
42Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsLeukemia20179
43Risk‐reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?Psycho-Oncology20199
44O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinomaAnnals of Oncology20209
45Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapseCancer Gene Therapy20219
46Positive Impact of Organized Physical Exercise on Quality of Life and Fatigue in Children and Adolescents With CancerFrontiers in Pediatrics20219
47BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancerCellular Oncology (Dordrecht)20229
48Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific AntibodyCells20208
49Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern ItalyCancers20218
50Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only − the SIOP 93–01 and 2001 protocolsEuropean Journal of Cancer20228